Thus, it would be interesting to determine, if there is a relationship between applied IL2/IL2mAb complex dose and predominant Treg cell phenotype that can be monitored in clinical applications of IL2, especially since the effects of low versus high dose IL2 treatment are currently investigated for the treatment of autoimmune diseases such as diabetes [47, 48]. The gene discussed is IL2; the disease is diabetes mellitus.